Christine Simmon has been named President and Chief Executive Officer at Food and Drug Law Institute (FDLI). Prior to joining FDLI, Christine served as Executive Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines (AAM). Her leadership contributed to AAM’s successful advocacy for pharmaceutical competition and improved market access. Concurrently, Christine served as Executive Director of the Biosimilars Council, the AAM subsidiary that advocates for greater access for patients to biosimilar medicines.